Episode Details

ValiRx PLC (LSE: VAL) CEO Mark Eccleston joins The Watchlist to discuss the company’s newly created subsidiary, ValiRx Animal Health Ltd., and why the veterinary oncology market could represent a major complementary opportunity for the company’s research platform.

In this episode, listeners will hear how ValiRx plans to leverage comparative oncology to develop treatments that benefit both animals and humans, while potentially accelerating commercialization timelines through faster regulatory pathways in animal health.

This discussion covers:

• The strategy behind launching ValiRx Animal Health Ltd.
• The size and growth of the global animal health market
• How comparative oncology benefits both veterinary and human medicine
• The company’s hub-and-spoke structure and SPV funding model
• What investors should watch from ValiRx over the next 12–24 months

Website:
https://www.valirx.com

Disclaimer:
This podcast is made in partnership with ValiRx PLC. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.